Skip to main content

Table 3 Number (%) of patients with adverse events, by body system and preferred term, by relation to study drug.

From: Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial

Table 3.1. Number (%) of patients with adverse events, by body system and preferred term, by relation to study drug.
  Imatinib mesylate
N = 95 not related related total
Gastrointestinal disorders    67(70.5)
   Nausea 9(9.5) 27(28.4) 36(37.9)
   abdominal pain 23(24.2) 4 (4.2)27(28.4)  
   Diarrhea 6(6.3) 20(21.1) 26(27.4)
   Vomiting 8(8.4) 9(9.5) 17(17.9)
   constipation 10(10.5) 4(4.2) 14(14.7)
   Flatulence 5(5.3) 6(6.3) 11(11.6)
   abdominal discomfort 8(8.4) 2(2.1) 10(10.5)
   Dyspepsia 2(2.1) 3(3.2) 5(5.3)
   abdominal pain 2(2.1) 2(2.1) 4(4.2)
   Subileus 4(4.2) -- 4(4.2)
   Melaena 3(3.2) -- 3(3.2)
   Stomatitis 3(3.2) -- 3(3.2)
General disorders    54(56.8)
   oedema peripheral 6(6.3) 23(24.2) 29(30.5)
   fatigue 9(9.5) 13(13.7) 22(23.2)
   oedema 1(1.1) 9(9.5) 10(10.5)
   pain 7(7.4) 2(2.1) 9(9.5)
   asthenia 3(3.2) 6(6.3) 9(9.5)
   fever 6(6.3) 1(1.1) 7(7.4)
   chest pain 33.2) -- 3(3.2)
Musculoskeletal and connective tissue disorders    35(36.8)
   muscle cramp 2(2.1) 15(15.8) 17(17.9)
   arthralgia 8(8.4) 2(2.1) 10(10.5)
   pain (extremities) 6(6.3) -- 6(6.2)
   back pain 4(4.2) 1(1.1) 5(5.3)
   myalgia 1(1.1) 3(3.2) 4(4.2)
Skin and subcutaneous tissue disorders    34(35.8)
   periorbital oedema -- 8(8.4) 8(8.4)
   exanthema 1(1.1) 6(6.3) 7(7.4)
   face oedema -- 6(6.3) 6(6.3)
   hyperhidrosis 3(3.2) 2(2.1) 5(5.3)
   alopecia 1(1.1) 2(2.1) 3(3.2)
   dry skin -- 3(3.2) 3(3.2)
   erythema -- 3(3.2) 3(3.2)
   night sweats 2(2.2) 1(1.1) 3(3.2)
   pruritus -- 3(3.2) 3(3.2)
   scar pain 3(3.2) -- 3(3.2)
Table 3.2. Number (%) of patients with adverse events, by body system and preferred term, by relation to study drug.
N = 95 Imatinib mesylate
  not related related total
Eye disorders    27(28.4)
   eyelid oedema -- 23(24.2) 23(24.2)
   conjunctivitis -- 6(6.3) 6(6.3)
   lacrimation increased -- 3(3.2) 3(3.2)
Nervous system disorders    23(24.1)
   dizziness 3(3.2) 8(8.4) 11(11.6)
   headache 6(6.3) 3(3.2) 9(9.5)
   paraesthesia -- 3(3.2) 3(3.2)
Blood and lymphatic system disorders    21(22.1)
   anaemia 7(7.4) 9(9.5) 16(16.8)
   leukopenia -- 4(4.2) 4(4.2)
Psychiatric disorders    19(20.0)
   insomnia 8(8.4) 1(1.1) 9(9.5)
   anxiety 5(5.3) -- 5(5.3)
   depression 3(3.2) 2(2.1) 5(5.3)
   sleep disorder 2(2.1) 2(2.1) 4(4.2)
Metabolism and nutrition disorders    18(19.0)
   anorexia 7(7.4) 4(4.2) 11(11.6)
   hypokalaemia 6(6.3) 1(1.1) 7(7.4)
   hyperuricaemia 3(3.2) -- 3(3.2)
Infections    18(19.0)
   nasopharyngitis 6(6.3) -- 6(6.3)
   urinary tract infection 3(3.2) -- 3(3.2)
Respiratory, thoracic and mediastinal disorders    12(12.6)
   cough 4(4.2) -- 4(4.2)
   pleural effusion 3(3.2) -- 3(3.2)
Vascular disorders    9(9.5)
   hypertension 4(4.2) -- 4(4.2)
Laboratory findings    37(39.0)
   blood lactate dehydrogenase increased 6(6.3) 6(6.3) 12(12.6)
   blood bililrubin increased 2(2.1) 8(8.4) 10(10.5)
   blood alkaline phosphatase increased 5(5.3) 4(4.2) 9(9.5)
   blood creatinine increased 2(2.1) 6(6.3) 8(8.4)
   blood urea increased 3(3.2) 4(4.2) 7(7.4)
   alanine aminotransferase (ALT) increased 2(2.1) 4(4.2) 6(6.3)
   aspartate aminotransferase (AST) increased 2(2.1) 4(4.2) 6(6.3)
   blood uric acid increased 6(6.3) -- 66.3)
   haemoglobin decreased 1(1.1) 4(4.2) 5(5.3)
   hepatic enzyme increased 1(1.1) 3(3.2) 4(4.2)